Variation in glycosylation can impact the safety and efficacy profiles of a therapeutic product. Therefore, continuous monitoring of glycosylation patterns is essential in biopharmaceutical development and manufacturing. With the right tools, glycosylation management can be uncoupled from the entangled processes of fermentation.
This enables separate strategies to optimize glycosylation and yield, granting greater control over each. Certain glycoforms can be enriched in downstream processing using discrete enzymatic reactions with clear kinetics and predictable outcomes.
Glycosylation has the potential to make or break the successful market entry of a drug. Learn about the creation of high levels of galactosylation or sialylation to unambiguously select and implement the structure with the best therapeutic and pharmacokinetic profile.
Gains from in vitro glycoengineering:
- Time and cost-saving generation of glycan variants to develop improved drugs
- Optimized glycosylation without compromising other CQAs or product yield
- Improved lot-to-lot consistency to reduce risk of product quality variation and resulting delays
- Generation of glycoprofiles which may not otherwise be generated
- Streamlined analytics in comparability studies
Discover gains for your application with in vitro glycoengineering.
No more resources wasted on uncertain tweaking of the bioprocess, leading to faster development as well as improved control of the manufacturing process.
Presented by
Roland Dorn,
International Product Manager, CustomBiotech, Roche Diagnostics
Roland Dorn is responsible for the in vitro glycoengineering portfolio as international product manager at Roche CustomBiotech.
Marco Thomann,
Manager Pharma Technical Development Analytics, Roche Diagnostics GmbH
Marco Thomann is head of an analytical lab in Roche Pharma Technical Development. He was involved in the development of glycoenzymes, uses the in vitro glycoengineering technology for his daily work and will explain some of these applications.
